论文部分内容阅读
目的通过检测临床指标的变化,观察应用环孢素(CsA)联合中剂量强的松及地尔硫卓(CsA三联疗法)治疗小儿难治性肾病综合征的临床疗效。方法 2004年10月至2008年10月在河南省人民医院儿科住院的27例难治性肾病综合征患儿运用CsA三联疗法进行治疗。进行1年的随访,在治疗前、治疗后3、6、12个月分别记录24 h尿蛋白定量、尿NAG酶、肝功能(ALT)、肾功能(SCR)及环孢素血药浓度指标的变化,并记录不良反应。应用SPSS 17.0软件进行统计学分析。结果 27例接受CsA三联疗法治疗后20例(74.07%)患儿病情缓解,其中完全缓解14例(51.85%),部分缓解6例(22.22%),无效7例(25.93%)。22例患儿进行了肾穿刺活检,MCD 10例总缓解率为90.00%,MsPGN 9例总缓解率为77.78%,3例FSGS缓解1例。病例中23例出现毛发增多的现象,4例齿龈增生,2例出现血压增高现象,4例出现轻微的胃肠道反应,CsA治疗过程未出现明显肾毒性反应。结论应用环孢素三联疗法治疗小儿难治性NS,能明显提高CsA的疗效,减少CsA用量并降低CsA的不良反应,同时能促进肾功能的恢复,改善小儿难治性NS临床检测指标。
Objective To observe the clinical effect of cyclosporine (CsA) combined with mid-dose prednisone and diltiazem (CsA triple therapy) in the treatment of refractory nephrotic syndrome in children by detecting the changes of clinical indexes. Methods From October 2004 to October 2008, 27 children with refractory nephrotic syndrome admitted to Pediatrics Department of Henan Provincial People’s Hospital were treated with CsA triple therapy. The patients were followed up for 1 year. Urinary protein, urine NAG, ALT, SCR and cyclosporine blood concentration were recorded before treatment and 3, 6 and 12 months after treatment respectively. The changes and record the adverse reactions. Application SPSS 17.0 software for statistical analysis. Results Twenty-seven patients (74.07%) had complete remission after treatment with CsA triple therapy. Among them, 14 were completely relieved (51.85%), 6 were partially relieved (22.22%) and 7 were ineffective (25.93%). Twenty-two children underwent renal biopsy. The overall response rate of MCD was 90.00% in 10 cases, 77.78% in 9 cases of MsPGN and 1 case in 3 cases of FSGS. There were 23 cases of hair growth, 4 cases of gingival hyperplasia, 2 cases of increased blood pressure, 4 cases of mild gastrointestinal reactions, CsA treatment did not show significant nephrotoxic reaction. Conclusion The application of cyclosporin triple therapy in children with refractory NS can significantly improve the efficacy of CsA, reduce the dosage of CsA and reduce the adverse reactions of CsA, and can promote the recovery of renal function and improve the clinical indexes of refractory NS in children.